Absci and Caltech Collaborate to Accelerate Affordable HIV Therapeutic Vaccine
Absci, a biotech firm based in Vancouver, Washington, received a grant from the Bill & Melinda Gates Foundation to fund its partnership with the California Institute of Technology.
The two entities are combining their research and technology resources to develop a low-cost HIV vaccine. No cure currently exits for HIV and, while treatments are available, they are high in price and unobtainable by many low income or underserved patients. Absci and Caltech hope to improve both accessibility and affordability with this grant.
“We are thrilled to receive this grant from the Bill & Melinda Gates Foundation,” said Dr. Stephen Mayo, Caltech professor and project co-leader. “This collaboration with Absci allows us to combine our expertise and work towards a common goal of developing affordable HIV therapeutic vaccinations that can save lives and bring hope to millions.”